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Available online 15 November 2016Autoimmune diseases are characterized by chronic inﬂammatory reactions localized to an organ or organ-
system. They are caused by loss of immunologic tolerance toward self-antigens, causing formation of autoanti-
bodies that mistakenly attack their own body. Psoriasis is a chronic inﬂammatory autoimmune skin disease in
which the underlying molecular mechanisms remain elusive. In this review, we present evidence accumulated
throughmore than three decades that the serpin-derived protein Pso p27 is an autoantigen in psoriasis and prob-
ably also in other chronic inﬂammatory diseases.
Pso p27 is derived from the serpin molecules SERPINB3 and SERPINB4 through non-canonical cleavage by mast
cell chymase. In psoriasis, it is exclusively found in skin lesions andnot in uninvolved skin. The serpins are cleaved
into three fragments that remain associated as a Pso p27 complex with novel immunogenic properties and in-
creased tendency to form large aggregates compared to native SERPINB3/B4. The amount of Pso p27 is directly
correlated to disease activity, and through formation of complement activating immune-complexes, Pso p27 con-
tribute to the inﬂammation in the skin lesions. SERPINB3/B4 are expressed in skin ﬁbroblasts and keratinocytes,
but normally absent in mast cells. Overexpression of the serpins may be induced by inﬂammation and hypoxia,
resulting in mast cell uptake via yet unknown mechanisms. Here the generation and subsequent release of Pso
p27 aggregates may promote an inﬂammatory loop that contributes to the chronicity of psoriasis and other au-
toimmune diseases.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Autoimmune disease is a common term of diseases caused by im-
mune responses against self-antigens. Such responses may be triggered
via differentmechanisms, including abnormal alteration of self-antigens
or exposure to microbial antigens harbouring epitopes similar to those
found in humans [1]. The disease is deﬁned according to the affected
organ or organ system and it has been postulated that the inﬂammation
is caused by immune reaction toward tissue speciﬁc autoantigens. How-
ever, despite considerable efforts the search for such autoantigens has
not given breakthroughs in our understanding of disease mechanisms.
There are some important facts that should be taken into account in the
search for autoimmune disease mechanisms: 1) The inﬂammation is usu-
ally restricted to parts of the affected organ or organ system. This argues
against a tissue speciﬁc autoantigen, which would rather mediate
involvement of the whole organ. 2) The inﬂammation is in principleence and Technology, Faculty of
and Women's Health, Postbox
. This is an open access article underchronical. This argues for a positive feedbackmechanismwhere inﬂamma-
tory consequences give rise to more inﬂammation. 3) The coincidental oc-
currence ofmore than one autoimmune condition in the samepatient. This
indicates common disease mechanisms in various autoimmune diseases.
Psoriasis is an inﬂammatory skin disease that fulﬁls all three criteria.
Several studies suggest that activated T-cells play a role in triggering
and/or maintaining the disease [2]. It is also a clear HLA-association
with psoriasis, consistent with T-cell mediated autoimmunity, and the
highest relative risk is associated with HLA-C*06:02 [3]. More than
40 years ago Jablonska et al. [4] reported more IgG bound to the epider-
mis and stratum corneum of psoriatic lesions than in other inﬂamma-
tory and hyperkeratotic diseases. Since then, several psoriatic
autoantigens have been suggested, including keratins structurallymim-
icking bacterial M-proteins [5], ezrin, maspin, PRDX2 and HSP27 [6]
basement membrane laminin [reviewed in [7]], the antimicrobial pep-
tide LL37 [8] and the melanocyte protein ADAMTSL5 [9]. However, nei-
ther of these have been found to be present among all psoriasis patients.
Conversely, Pso P27, a proteolytically processed form of the SERPINB3
and SERPINB4, is abundantly expressed in psoriatic lesions from all pa-
tientswe have examined so farwhile it is not found in unaffected skin in
the same patients. The present review will outline research throughthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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highlighting its potential role as an autoantigen in psoriasis as well as
in several other inﬂammatory diseases.
2. The presence of virus-like particles in psoriasis
In an approach to identify etiological factors in psoriasis, it is appro-
priate to compare psoriatic skin lesions and uninvolved/healthy skin
from the same patient. Several decades ago electron microscopic analy-
ses of psoriatic skin lesions demonstrated subcellular virus-like particles
that were not present in the uninvolved healthy skin ([10,11], Fig. 1).
Membrane coated virus-like particles were released to the culture me-
dium during cultivation of tissue from psoriatic lesions [11] and similar
particles were obtained from the urine of psoriatic patients with exten-
sive disease activity [12,13]. Puriﬁcation of the particles by isopycnic
ultracentrifugation and subsequent denaturing size-exclusion chroma-
tography demonstrated that the particles contained three core proteins
with estimatedmolecularmasses of 12, 15 and 27 kD, respectively, [13].
Based on their morphology, buoyant density and molecular mass of the
core proteins, it was hypothesised that the particles could be endoge-
nous retroviruses. This was also in line with a previous observation of
retroviral immune complex deposits in skin biopsies in another autoim-
mune disease, systemic lupus erythematosus [14]. However, neither
polyadenylated RNA nor reverse transcriptase could be detected in the
particles [15]. Even if the particles did not turn out as infectious agents,
their potential role in the pathogenesis of psoriasis remained
unaddressed.
3. Immune reaction against protein constituents of virus-like parti-
cles — the autoantigen Pso p27
Chronic inﬂammation with inﬁltration of inﬂammatory cells in the
skin lesions is a characteristic feature in psoriasis. However, despite ex-
tensive research, no infectious candidate has been identiﬁed as causal
agent in the immune reactions. As the virus-like particles were present
in the skin lesions only, it seemed appropriate to investigate whether
the particle proteins could be immunogenic and play a role in the im-
mune reactions in psoriasis. To follow this assumption the major inter-
nal protein from the virus-particles, p27, was selected as reference
protein. Using rabbit antiserum against p27 a cross-reacting protein
was extracted from psoriatic scale. Even if the particle-associated pro-
tein and the serological cross-reacting protein obtained from psoriatic
lesions had similar molecular mass they were not necessarily identical.
Thus, to differentiate the two proteins, the latter was named Pso p27
[16].N
C
Fig. 1. Intracellular spherical bodies in psoriatic lesion and extracellular membrane coated
particles likely released via budding or cell destruction demonstrated by electron
microscopy [11].Large amounts of Pso p27 can be extracted from psoriatic scale and
with reference to serum albumin the concentration of Pso p27 in scale
exceeds that in serumwith a factor of 106 (17). This underlined the po-
tential of Pso p27 as a disease associated protein. To elucidate the poten-
tial role of Pso p27 as an autoantigen, antibodies in psoriatic scale
extract were analysed by indirect ELISA with p27 or Pso p27 as antigen
[18]. The relative concentration of anti-Pso p27 speciﬁc antibodies ex-
tractable from psoriatic scale exceeded that of serum from the same pa-
tient with a factor of 103 (Fig. 2). These observations indicated the role
of Pso p27 as a locally generated immunogen [18,19]. Furthermore,
immune-complexes formed by the Pso p27 antigen and corresponding
antibodies from psoriatic scale were shown to activate the complement
system and thus emphasized the signiﬁcance of Pso p27 in the inﬂam-
matory process [20]. When scale antibodies were used in an approach
to identify candidate antigens in the psoriatic scale extract, the Pso
p27 antigen was identiﬁed as the most prominent candidate [19]. Fur-
thermore, use of scale antibodies in indirect immunoﬂuorescence mi-
croscopy of thin sections of psoriatic lesions revealed antigens in a
sub-fraction of dermal cells identical to those recognised by anti-Pso
p27 antibodies [Fig. 3, [19]].
Based on these ﬁndings it was concluded that Pso p27 appear as a
major antigen in the immune reactions in psoriasis [19].4. Expression of Pso p27 positively correlates with disease activity
Immunoﬂuorescence microscopy of skin biopsies revealed Pso p27
positive cells in every psoriatic skin lesion investigatedwhile noﬂuores-
cence was detectable in uninvolved psoriatic skin [21–23]. This demon-
strated that Pso p27 was not a common skin protein but rather a locally
expressed antigen (Fig. 4). The monoclonal mouse anti-Pso p27 anti-
bodies were shown to be highly speciﬁc [22–25] and represent power-
ful tools for semi-quantiﬁcation of Pso p27 [24]. When following
patients treated with cyclosporin A, we observed a positive correlation
between response to treatment and diminishing concentrations of Pso
p27 in the selected skin lesions [22]. Equivalent results were obtained
when patients were treated with herbal extracts according to tradi-
tional Chinese medicine [23] as exempliﬁed in Fig. 5. Both studies
were performed double blinded with semi-quantifying the prevalence
of Pso p27 positive cells in the biopsies. Spontaneous ﬂuctuations in dis-
ease activity also correlate with expression of Pso p27.Ab
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Fig. 2. Comparison of anti-Pso p27 antibodies in psoriatic scale extract and serum from the
same patient demonstrated by indirect ELISA [18].
Fig. 3. Binding of scale antibodies (A) and rabbit anti-Pso p27 antibodies (B) to a thin
section of a psoriasis lesion demonstrated by indirect immunoﬂuorescence microscopy
[19].
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Inﬁltration of inﬂammatory cells is a characteristic feature of psori-
atic lesions [26] and it was expected that the Pso p27 positive cells
were among these cells. In an approach to characterise the Pso p27 pos-
itive cells, double labellingwith anti-Pso p27 antiserumandmonoclonal
antibodies against speciﬁc surface membrane proteins on various im-
mune cells was performed without coincidence. After elimination of
lymphocytes and monocytes as candidates, we ﬁnally combined anti-
Pso p27 antiserum and an enzyme assay speciﬁc formast cell associated
tryptase (Fig. 6). Given entirely concomitant staining for tryptase in the
Pso p27 positive cells, we concluded that these cells were mast cells
[21]. The absence of Pso p27 in mast cells in uninvolved psoriatic skin
suggested that the presence of Pso p27 was a unique characteristic of
the mast cells in the skin lesions [21].
These observations indicated a key role of mast cells in the genera-
tion of Pso p27 and substantiated the presumption of Pso p27 as an im-
portant antigen in the pathogenesis of psoriasis.Fig. 4. Binding of speciﬁc monoclonalmouse antibodies against Pso p27 to thin sections of
a psoriatic lesion (A) and uninvolved skin (B).6. Pso p27 — a posttranslational modiﬁcation of SERPINB3/B4
To map out the mechanisms underlying generation of Pso p27, we
proceeded to sequence the protein by N-terminal Edman degradation
[27]. The sequence showed homology with squamous cells carcinoma
antigen (SCCA), and this relationship was strengthened by Yu et al.
who demonstrated that a monoclonal antibody against Pso p27 bound
to an epitope on SCCA2b [25]. Due to technological andmethodological
progress within mass spectrometry during the last decades, sequencing
of larger peptides and proteins has improved considerably, and this
opened up for more comprehensive characterisation of Pso p27. How-
ever, despite access to extensive quantities of Pso p27 from psoriatic
scale, puriﬁed through immune-chromatography and preparative
SDS-PAGE, analyses of the sequence data gave unexpected challenges
due to the presence of non-canonical amino acids. The underlying rea-
son for this is likely that Pso p27 was isolated from skin, which had
been exposed to oxygen and ultraviolet light and leading to abundant
protein oxidation. When this was accounted for in the database
searches we found that the amino-acid sequence of Pso p27 shared ho-
mology with distinct sequences in both SERPINB3 (SCCA1) and
SERPINB4 (SCCA2) [28]. Pso p27, which is a smaller protein compared
to the native serpin molecules, was found to represent a well-deﬁned
core structure of SERPINB3/B4 lacking the N-terminal and C -terminal
ends. Based on these ﬁndings we postulated that Pso p27 is generated
through speciﬁc enzymatic digestion of the serpin molecules by highly
speciﬁc endopeptidases [28]. The concomitant presence of Pso p27
and SERPINB3/B4 in mast cells in psoriatic lesions [29] established the
mast cell speciﬁc endoproteases chymase and tryptase as candidates
in catalysing the transformation of SERPINB3/B4 to Pso p27.
7. Generation of Pso p27 from recombinant SERPINB3
Overexpression of SERPINB3/B4 in epidermal cells in psoriatic le-
sions has been demonstrated by Takeda et al., [30]. However, as
shown in Fig. 7, SERPINB3 is also present in dermal cells.
To examine whether Pso p27 could be generated from serpins by
mast cell proteases, we employed puriﬁed recombinant full-length
SERPINB3. Whereas no cleavage of SERPINB3 was observed when incu-
bated with mast cell tryptase, three fragments were generated after
treatmentwithmast cell chymase. Here, the largest fragmentwas iden-
tical to Pso p27 and two additional fragments represented the N-
terminal - and the C-terminal ends of SERPINB3 [31] (Fig. 8A).
X-ray crystallographic analyses demonstrated that the N-terminal
and the C-terminal fragments remained associated with Pso p27,
forming a Pso p27-complex (Fig. 8B) with conspicuous structural simi-
larities to SERPINB3 (Fig. 8C,D). However, despite the conformational
similarities between the Pso p27-complex and SERPINB3, several dis-
tinct physicochemical and antigenic differences were found: 1) Unique
monoclonal antibodies against Pso p27 did not recognise corresponding
epitopes on SERPINB3 [29,31,32]. 2) The Pso p27-complex formed large
aggregates compared to SERPINB3 [32]. 3) A polyclonal antiserum
against the N-terminal end of SERPINB3 did not bind to the Pso p27-
complex in vivo or in vitro [32]. The latter suggests that in the aggregated
Pso p27 complex, the antibody-binding epitope is hidden by a highly or-
dered structure organization [32].
Based on these observations, we concluded that Pso p27 is generated
from SERPINB3/B4 by enzymatic digestion with mast cell chymase. The
three fragments remain associated in a Pso p27-complex in which the
core subunit has an extended β-sheet conformation and that has a pro-
pensity to form large aggregates with deﬁned structures, thus resem-
bling the mechanistic foundation of many serpinopathies [33].
8. Serpins are metastable protease inhibitors
Serpins, of which 37 have been described in humans [34], are serine-
or cysteine protease inhibitors that regulate a wide range of
Fig. 5. Pso p27-expression in biopsies from psoriatic lesions before (A), and after (B, C) treatment with herbal extract demonstrating both various response to treatment and correlation
between Pso p27 expression and disease activity.
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and are also involved in angiogenesis and apoptosis [35]. They share a
common three-dimensional structure composed of three β-sheets (A-
C), 8 or 9 α-helices and a ﬂexible reactive centre loop (RCL) that serves
as a pseudo-substrate for their target proteases. In the unbound condi-
tion, serpins exist in a metastable, high-energy state, and the energy re-
lieved by interactionwith the target proteases is clue to their inhibition.
In the standard inhibitory mechanism of serine proteases, residues in
the RCL of the serpin matchwith residues in the active site of the target
protease. Upon binding, a scissile (P-P1′) bond of the RCL is cleaved by
the protease leading to the formation of a stable acyl-enzyme interme-
diatewhere the protease forms an ester bondwith the C-terminal of the
cleaved RCL. The new C-terminal of the loop then inserts as an addi-
tional antiparallel strand into β-sheet A and translocates the protease
to the opposite pole of the serpin molecule, thereby crushing the prote-
ase against the serpin surface rendering both the serpin and the prote-
ase irreversibly inactivated [36]. Some cross-class serpins targeting
cysteine proteases may deviate from this behaviour. Thus, when
SERPINB3 was incubated with papain, a stable covalent complex was
not formed [37]. Moreover in the same study papain partially regained
its activity when all SERPINB3was cleaved SERPINB3 and SERPINB4 be-
long to the clade B serpins that encompass 13 human members [38].
They were originally puriﬁed from squamous cell carcinoma tissue, as
the major component of the TA-4 antigen [39]. The two proteins are
co-expressed in many normal tissues, including several areas of theFig. 6. Coincidental detection of Pso p27 positive cells (A) and tryptase containing cells
(B) in a thin section from a psoriasis lesion strongly indicates that the Pso p27 cells are
mast cells.skin, and elevated levels have been found in many epithelial malignan-
cies [40,41] [Reviewed in [42]].
The SERPINB3 and B4 polypeptide chains both contain 390 residues
and share an overall 92% sequence identity except in the RCL loop, in
which the identity drops to 63% (Fig. 9). The differences in the RCL
loops also underlie the target speciﬁcities of the two serpins. Whereas
SERPINB3 has been shown to inhibit papain-like cysteine proteases
such as papain and cathepsin S, -K and -L [43,44], SERPINB4 inhibits
both cysteine proteases [45] and serine proteases [46].
Based on target-enzyme speciﬁcity of other inhibitory serpins, the
RCL of SERPINB3 was originally predicted to harbour Ser-Ser at P1 and
P1′ [47]. Notably, this cleavage site does not conform well to the sub-
strate preference reported formast cell chymase,which strongly prefers
an aromatic residue at P1 [48]. Both Pso p27 isolated from psoriatic skin
and Psop27 generated by cleavage of recombinant SERPINB3 reveal two
unique cleavage points at Tyr73/His74 and Val349/Val350 (Fig. 9). These
cleavages should occur in both serpins in vivo, since peptides distinct
to either serpin were found in Pso p27 isolated from psoriatic plaque
[28]. The N-terminal cleavage site (Tyr-His) present in both SERPINB3
and B4 conformswell to the reported preference of an aromatic residue
at P1, whereas His at P1′was not reported in a previous study [48]. Thus30 µm
Fig. 7. Confocal image displaying a crosscut papilla of a psoriatic lesion with SERPINB3/B4
positive cells (red) and Pso p27 positive cells (green).
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Fig. 8. A) Cleavage of SERPINB3/B4 by mast cell chymase yields a core fragment (red) identical to Pso p27 isolated from psoriatic scale, and N-terminal (green) and C-terminal (blue)
fragments. B) The X-ray crystallographic structure of chymase-treated SERPINB3 revealed that the N- (green) and C-terminal (blue) fragments remained bound to the core fragment
(red) in a Pso p27 complex. Residues highlighted in the C-terminal fragment are from the cleavage border in SERPINB3 (VGF) and SERPINB4 (VVV). Bottom panels: Cartoon
illustrations of the Pso p27 complex (C) and SERPINB3 (D). The white arrow in (C) highlights the cleaved RCL inserted as a novel antiparallel strand in β-sheet A.
14 O.-J. Iversen et al. / Clinical Immunology 174 (2017) 10–17the substrate preference of mast cell chymase appears to be broader
than previously reported.
Regulatory mechanisms are likely in place to avoid the apparent
non-speciﬁc cleavage of SERPINB3/B4 in vivo, e.g. by physical separation
of the chymase and serpins under normal circumstances. Our immuno-
ﬂuorescence analyses revealing absence of Pso p27 in mast cells in nor-
mal skin indicate that SERPINB3/B4 are not present in these cells. This
was very recently supported by a comprehensive proteomic study of
human skin mast cells in which 17 serpins were identiﬁed, but not
SERPINB3/B4 [49]. Conversely, the same study robustly identiﬁed
SERPINB3 in human dermal ﬁbroblasts and both SERPINB3 and
SERPINB4 in epidermal keratinocytes.
In summary, the above studies suggest that SERPINB3/B4 are not
natural targets for mast cell chymase in vivo, Nevertheless, both serpins
contains motifs that can be cleaved to produce Pso p27. Thus, the
serpins and the mast cell chymase are likely spatially separated in
healthy tissues.E G EV A A A A A V L S SSV VVT P TEE
SERPINB3
Reactive centre loop
Proximal hinge Exposed loop
SERPINB4
E G G GA A A A A A V F S S SPVT T TEE
338 359
P 15 4 214 12 11 10 9 7 5 3 1 1’ 4’2’68 3’ 5’ 6’1316
17P 15 4 214 12 11 10 9 7 5 3 1 1’ 4’2’68 3’ 5’1316
Fig. 9. The RCLs in SERPINB3 and SERPINB4 encompassing residues 338 to 359 in both
proteins. Individual residues are coloured according to ClustalX [63] colour coding.
Green arrows indicate canonical cleavage sites associated with protease inhibition in
SERPIN B3 [64] and SERPINB4 [46]. Red arrow indicates (abnormal) cleavage of
SERPINB3 by mast cell chymase, which does not mediate formation of a covalent
intermediate.9. Mast cells may play a crucial role in mediating an autocrine in-
ﬂammatory loop
The underlying mechanisms causing SERPINB3/B4 overexpression
in psoriatic lesions remain poorly understood, but local production of
pro-inﬂammatory cytokines [50] most likely plays an important role.
At least three of the cytokines found to be overexpressed in psoriatic
skin, TNF-α [56] IL22 [57] and IL-6 (58), have been shown to promote
increased levels of SERPINB3/B4.
The concomitant presence of intact SERPINB3/B4 and Pso p27 in
mast cells [27,44] suggests that the transformation primarily takes
place within the mast cells. The mechanisms whereby SERPINB3/B4
are recruited into the mast cells from the surrounding cells in psoriatic
skin presently remain unknown. To the best of our knowledge, no re-
ceptors have been described that mediate cellular uptake of
SERPINB3/B4. However, the low density lipoprotein receptor-related
protein (LRP) is able to bind and internalize a wide range of structurally
diverse proteins, including serpins and their protease complexes and
activated forms of the pan proteinase inhibitor α2-macroglobulin
(α2M) [51,52]. A high-afﬁnity site for binding to LPR1 has been charac-
terized, and consists of a cluster of three Lys and one Arg residue. It is
noteworthy that SERPINB3/B4 contain several such basic clusters and
their potential to bind LRP1 thus rewards further examination. LRP1 is
amply expressed by human dermal ﬁbroblasts, and to a lesser extent
by skin mast cells [49]. We might thus speculate whether the high con-
centrations of SERPINB3/B4 in psoriatic lesions [30] by itself may cause
endocytosis into the skin mast cells.
After being processed by mast cell chymase, the generated Pso p27-
complexes show a tendency to form large aggregates and they may be
released from themast cell through a budding process or by cellular de-
struction (Fig. 1). Even if the molecular masses of the three peptide-
fragments in the Pso p27-complex deviate somewhat from the esti-
mated molecular masses of the internal proteins in the membrane
coated virus-like particles obtained from psoriatic patients [13], these
Fig. 11. Detection of Pso p27 in skin lesions from patients with psoriasis (A) and atopic
dermatitis (B), using monoclonal mouse antibodies [58].
15O.-J. Iversen et al. / Clinical Immunology 174 (2017) 10–17may in fact represent aggregated Psop27 complexes released frommast
cells as budding particles.
The immunogenic potential of Pso p27 results in generation of anti-
bodies and complement activating immune-complexes. This contrib-
utes to the inﬂammation through recruitment of inﬂammatory cells,
release of various cytokines [53,54] and inﬂammation associated hyp-
oxia [55,56] which will stimulate further expression of SERPINB3/B4.
Serpin molecules will in turn be taken up by mast cells and in this
way be substrate for generation of more Pso p27-complexes and gener-
ate a positive feedback loop that may explain the chronic inﬂammatory
reaction in the psoriatic skin lesions. Such a positive feedback loop is
modelled in Fig. 10. Biological agents against cytokines, such as anti-
TNF antibodies, have been shown to suppress the disease activity in var-
ious inﬂammatory diseases. As TNF is shown to stimulate synthesis of
SERPINB3/B4 we would expect the anti-TNF antibodies to inhibit this
stimulation and consequently suppress generation of the autoantigen
Pso p27.
10. A role of Pso p27 in other autoimmune diseases
Mast cells are supposed to play a key role in atopic dermatitis, in
which SERPINB3/B4 have been shown to be upregulated related to dis-
ease activity [57]. Moreover, Hammeren identiﬁed Pso p27-containing
cells in the skin lesions of atopic dermatitis [58] (Fig. 11). This correlates
with the observation made in psoriasis. It is thus reasonable to hypoth-
esize that the mechanisms for generation of Pso p27 are similar to that
of psoriasis. Furthermore, Pso p27 protein has been detected in effected
organs in various diseases like psoriasis arthritis [59], rheumatoid ar-
thritis [59], ankylosing spondylitis [59], chronic inﬂammatory bowel
diseases [17] and sarcoidosis [11,24] and indirectly through detection
of anti-Pso p27 antibodies in cerebrospinal ﬂuid from patients with de-
generative disc disorders [60].
Overexpression of serpin molecules has been demonstrated in asso-
ciation with many inﬂammatory diseases including cancer. It is tempt-
ing to reﬂect whether generation of Pso p27 and the positive feedback
mechanism modelled in Fig. 10 contribute to sustaining inﬂammatory
reactions in various diseases even if the inducing factors are different.
In support of this, a very recent meta-analysis that integrate RNAseqSerpin B3/B4
Chymase
cleavage
Aggregation
Pso p27
Fig. 10. Schematic model of the posttranslational modiﬁcation of SERPINB3/B4 synthesised i
aggregates in subcellular virus-like particles. A segment of the confocal micrograph image in
mast cell. (ROS; Reactive oxygen species).data from PBMCs of psoriatic patients, healthy individuals and patients
suffering from a wide range of other autoimmune diseases such as MS,
sarcoidosis and juvenile rheumatoid arthritis, most closely mirrored
the differentially expressed genes in psoriasis [61].Concluding remarks
If generation of the autoantigen Pso p27 is a common principle in
chronic inﬂammatory diseases, mediating a feedback cyclic process as
outlined in Fig. 10, interference in this process will open up for speciﬁc
therapeutic strategies. Suppression of inﬂammation in general e.g. by
TNFα inhibitors will likely interfere with the generation of SERPINB3/
B4. However, such inhibitors are not speciﬁc and mediate substantial
adverse effects [[62] and references therein]. Conversely, inhibition of
SERPINB3/B4 uptake into themast cells or inhibiting the aberrant cleav-
age reaction would represent speciﬁc approaches with potentially less
adverse effects. Preliminary results from our laboratory indicate that in-
hibitors of the cleavage reaction and formation of Pso p27 is strongly
inhibited by factors present in extracts of Chinese herbs used in tradi-
tional treatment of psoriasis. Such extracts are thus promising sourcesImmune
stimulation
Immune
complexes
Complement
activation
Inflammation
Interleukins
STAT-
signalling
External factors
(Pathogens, hypoxia, ROS,
injuries, allergens etc.)
5 µm
n epithelial cells, transformed to Pso p27 in mast cells, and releasedas Pso p27-complex
Fig. 7 Demonstrates proximity of a SERPINB3/4-containing cell and a Pso p27-containing
16 O.-J. Iversen et al. / Clinical Immunology 174 (2017) 10–17of identifying drug candidates or lead molecules for targeted therapy of
psoriasis and potentially also other autoimmune diseases.
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